W Garrett Nichols
Overview
Explore the profile of W Garrett Nichols including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fowler Jr V, Das A, Lipka-Diamond J, Ambler J, Schuch R, Pomerantz R, et al.
Clin Infect Dis
. 2024 Feb;
78(6):1473-1481.
PMID: 38297916
Background: Novel treatments are needed for Staphylococcus aureus bacteremia, particularly for methicillin-resistant S. aureus (MRSA). Exebacase is a first-in-class antistaphylococcal lysin that is rapidly bactericidal and synergizes with antibiotics. Methods:...
2.
Hill J, Nichols W, Marty F, Papanicolaou G, Brundage T, Lanier R, et al.
Blood
. 2020 Feb;
135(17):1447-1451.
PMID: 32076716
Human herpesvirus 6B (HHV-6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT). There are no randomized studies of antiviral treatments to prevent HHV-6B reactivation. Brincidofovir has high in vitro activity...
3.
Imlay H, Xie H, Leisenring W, Duke E, Kimball L, Huang M, et al.
Blood Adv
. 2020 Feb;
4(4):617-628.
PMID: 32074279
BK polyomavirus (BKPyV) has been associated with hemorrhagic cystitis (HC) after allogeneic hematopoietic cell transplantation (HCT), but the natural history of HC and factors associated with the clinical course are...
4.
Marty F, Winston D, Chemaly R, Mullane K, Shore T, Papanicolaou G, et al.
Biol Blood Marrow Transplant
. 2018 Oct;
25(2):369-381.
PMID: 30292744
Cytomegalovirus (CMV) infection is a common complication of allogeneic hematopoietic cell transplantation (HCT). In this trial, we randomized adult CMV-seropositive HCT recipients without CMV viremia at screening 2:1 to receive...
5.
Kimball L, Stevens-Ayers T, Green M, Xie H, Flowers M, Jerome K, et al.
Contemp Clin Trials Commun
. 2017 Feb;
4:84-89.
PMID: 28184381
Purpose: The logistics of conducting double-blinded phase III clinical trials with participants residing in remote locations are complex. Here we describe the implementation of an interventional trial for the prevention...
6.
Chittick G, Morrison M, Brundage T, Nichols W
Antiviral Res
. 2017 Jan;
143:269-277.
PMID: 28093339
Brincidofovir (BCV, CMX001) is an orally available, long-acting, broad-spectrum antiviral that has been evaluated in healthy subjects in Phase I studies and in hematopoietic cell transplant recipients and other immunocompromised...
7.
Price T, Boeckh M, Harrison R, McCullough J, Ness P, Strauss R, et al.
Blood
. 2015 Sep;
126(18):2153-61.
PMID: 26333778
High-dose granulocyte transfusion therapy has been available for 20 years, yet its clinical efficacy has never been conclusively demonstrated. We report here the results of RING (Resolving Infection in Neutropenia...
8.
Boeckh M, Nichols W, Chemaly R, Papanicolaou G, Wingard J, Xie H, et al.
Ann Intern Med
. 2015 Jan;
162(1):1-10.
PMID: 25560711
Background: Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined. Objective: To compare valganciclovir prophylaxis with polymerase chain reaction-guided preemptive therapy. Design: Randomized, double-blind trial. (ClinicalTrials.gov: NCT00016068). Setting: Multicenter...
9.
Raffi F, Rachlis A, Brinson C, Arasteh K, Gorgolas M, Brennan C, et al.
AIDS
. 2014 Nov;
29(2):167-74.
PMID: 25387312
Objectives: Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and superiority compared with efavirenz and ritonavir-boosted darunavir. We explored factors...
10.
Molina J, Ait-Khaled M, Rinaldi R, Penco G, Baril J, Cauda R, et al.
J Antimicrob Chemother
. 2009 Jun;
64(2):398-410.
PMID: 19515730
Background: APV102002 was an open-label study comparing a dual-boosted HIV-1 protease inhibitor (PI) [fosamprenavir/lopinavir/ritonavir (FPV/LPV/RTV; 1400 mg/533 mg/133 mg twice daily)] and a high dose of FPV/RTV 1400 mg/100 mg...